Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye.
This positive initial data from our ophthalmology program supports the potential efficacy of LTB4 and C5 inhibition in eye surface and back-of-the-eye diseases. Nomacopan as a dual action inhibitor of LTB4 and C5 has the potential to be a novel eye therapy in multiple ophthalmic indications, said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics. Akari intends to continue development of nomacopan and long acting nomacopan variants using both topical and intravitreal administration.
Poster Presentation at ARVO 2019Title: Targeting the leukotriene B4 pathway and/or complement C5 via dual-functional recombinant coversin (nomacopan) in Experimental Autoimmune Uveitis (EAU)
In a poster to be presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Vancouver on April 28, 2019, Dr Virginia Calder of the UCL Institute of Ophthalmology, London, and Akari Therapeutics, will announce the results of nomacopan and nomacopan variants in a preclinical model of (EAU).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.